Late-stage ovarian cancer shows promise in two-drug phase I trial
Wednesday, June 9, 2010 - 14:41
in Health & Medicine
The combination of decitabine and carboplatin appears to improve the outcome of women who have late-stage ovarian cancer. In an upcoming issue of the journal Cancer (online today), Indiana University researchers report four of 10 patients who participated in a phase I clinical trial had no disease progression after six months of treatment. One patient experienced complete resolution of tumor tissue for a period of time.